Scope of the journal

Scope of the Journal involves Molecular Pathobiology, cellular pathobiology, tumor and stem cell biology, metastasis, tumor suppressor, microenvironment and immunology, prevention and epidemiology, integrated systems and technology, therapeutics and targets. View More..

Special Sections

Articles published in the journal will also be included under the special section that falls within the scope of each section. The special sections are as follows:
Cancer stem cells | Innovative Therapies
Carcinogenesis | Organ Specific Cancers
Radiation and Imaging
Epidemiology, Genetics and Genomics

Case report | Organ Specific Cancers Open Access

Lung cancer or sarcoidosis: A diagnostic dilemma

Poornima Ramadas, Prathik Krishnan, Aakriti Pandita, Manju Paul, Christopher Curtiss, Ajeet Gajra
Journal of Cancer Therapeutics & Research 5 : 2

Original Research | Carcinogenesis Open Access

PARP-1 modulates β1-integrin/NF-κB-mediated radioresistance in human breast cancer

David Raleigh, Kazi M Ahmed, Hui Zhang, Shabnam Ziaee, Catherine C Park
Journal of Cancer Therapeutics & Research 5 : 1

Case report | Organ Specific Cancers Open Access

A rare case of mucoepidermoid carcinoma of the lingual tonsil with cervical lymph node metastases

Claire M Lawlor, Ryan E Nelson, Meggie E Doucet, Paul L Friedlander
Journal of Cancer Therapeutics & Research 4 : 1

Review | Carcinogenesis Open Access

Cancer and stress: what’s matter? from epidemiology: the psychologist and oncologist point of view

Nerina Denaro, Letteria Tomasello, Elvio Grazioso Russi
Journal of Cancer Therapeutics & Research 3 : 6

Original Research | Organ Specific Cancers Open Access

Outcomes for critically ill patients with haematological malignancies in specialist and non-specialist centres in the United Kingdom

Peter Andrew Hampshire, Richard Pugh, Phillip Hajimichael
Journal of Cancer Therapeutics & Research 3 : 5

Original Research | Epidemiology, Genetics and Genomics Open Access

A study of incidence of EGFR mutations in non-smoker adenocarcinoma of the lung: disparity between north and south indian patients

Manish Pungliya, Minhas Sachin, Nagasamy Soumittra, Patil Shekar, Aggarwal Shyam
Journal of Cancer Therapeutics & Research 3 : 4

Original Research | Organ Specific Cancers Open Access

Are mutations in K-RAS, BRAF and PIK3CA genes critical for response to adjuvant trastuzumab treatment in patients with HER-2 positive breast cancer?

Anne Marie Bak Jylling, Anders Aamann Rasmussen, Erik Hugger Jakobsen, René dePont Christensen, Flemming Brandt Sørensen
Journal of Cancer Therapeutics & Research 3 : 3

Original Research | Organ Specific Cancers Open Access

The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer

Priyanka Sharma, Shane R. Stecklein, Bruce F. Kimler, Geetika Sethi, Brian K. Petroff, Teresa A. Phillips, Ossama W. Tawfik, Andrew K. Godwin, Roy A. Jensen
Journal of Cancer Therapeutics & Research 3 : 2

Original Research | Epidemiology, Genetics and Genomics Open Access

Apoptosis-related single nucleotide polymorphisms and the risk of non-small cell lung cancer in women

Anand Pathak, Angela S. Wenzlaff, Paula L. Hyland, Michele L. Cote, Greg R. Keele, Susan Land, Matthew L. Boulton, Ann G. Schwartz
Journal of Cancer Therapeutics & Research 3 : 1

Original Research | Innovative Therapies Open Access

PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma

Giselle Saulnier Sholler, Erika A. Currier, Akshita Dutta, Marni A. Slavik, Sharon A. Illenye, Maria Cecilia F. Mendonca, Julie Dragon, Stephen S. Roberts, Jeffrey P. Bond
Journal of Cancer Therapeutics & Research 2 : 21

View All articles ..

Editor-in-Chief

Prof. G. J. Peters
acting Head for the Laboratory Medical Oncology, VU University Medical Center, Netherlands. The major research interests of Prof. Peters include all aspects of pharmacology of anticancer agents, with emphasis on antifolates, other antimetabolites, platinum analogs, taxanes and more recently anti-signalling agents and third generation targeted-agents.

Senior Editors

Dr. Piero Picci
is presently acting as a Coordinator for IOR Director of the Laboratory of Experimental Oncology and President of the Italian Sarcoma Group and Director Laboratory of Experimental Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy. Dr. Piero is founder and member of the Board of the "Association for Study and Research in Musculo-skeletal Tumors". His major interest are focused on Diagnosis of bone tumors, Musculo-skeletal oncology, Bone tumors and Paediatric orthopaedic oncology.

Prof. Hallgeir Rui
Professor of Cancer Biology, Medical Oncology and Pathology at Thomas Jefferson University, Philadelphia, PA. He serves as the Scientific Director of the Jefferson Breast Care Center and is the Leader of Kimmel Cancer Center's Biology of Breast Cancer Program. Dr. Rui and his team have invented new high-density tissue arraying technology for high-throughput in situ biomarker studies. His major research interest focused on prolactin-JAK-STAT signaling in breast cancer, Loss of active STAT5 is an independent marker of poor prognosis and also an independent predictive marker of resistance to antiestrogen therapy.

Dr. Paolo Fortina
Professor of Cancer Biology, Jefferson Kimmel Cancer Center. He has completed his Ph.D. in Pediatrics, University of Turin School of Medicine, Torino, Italy. He is been acting as Adjunct Associate Professor of Pediatrics, University of Pennsylvania School of Medicine. His major research and Clinical Interest are focused on Genomics, technology and assay development in genomics, SNP genotype and CNV analysis for GWAS, gene discovery, pharmacogenomics .

Dr. Jacques E. Nor
Professor Of Cariology, Restorative Sciences, and Endodontics School of Dentistry, University of Michigan. He is been Honorary Professor, Oral Biology, University of Birmingham, UK. Dr. Nör research interests are focused on the cellular and molecular regulation of tumor angiogenesis. In addition, his research group has worked on the use of stem cells for the engineering of dental pulps.

Prof. Jiaoti Huang
Director, Urologic Pathology, Professor of Pathology and Laboratory Medicine. Dr. Jiaoti has Hospital Affiliation from Ronald Reagan UCLA Medical Center, USA. His research interested is majorly focused on Genitourinary Pathology, Surgical Pathology, Urologic Pathology.

Journal of Cancer Therapeutics & Research Subject Areas

Cancer Biology, Cancer Therapy, Cancer Prevention, Cancer Epidemiology, Oncology, Cancer Genetics, Cancer Genomics, Translational Therapeutics, Lung Cancer, Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma , Genitourinary Cancer, Gynecologic Cancer, Central Nervous System Tumors, Head and Neck Cancer, Lymphoma, Skin Cancers.

Tweets